The Remaining toughness is a big portfolio footprint which will still negotiate with external manufacturers. If US incentives increase for community drug compound do the job, Viatris may need partnerships as an alternative to owned property to qualify. The true secret operational chance is supplier concentration and slower remediation cycles https://www.tjcy.com/industry-information/api-vs-fdf-vs-intermediates-what-s-the-difference.html